



Supplementary Figure S1. Changes in HOMA2-R and disposition by concomitant medication for diabetes in the pemafibrate group from baseline. Data are shown as the median change (95% confidence interval). GLP-1RAs, glucagon-like peptide-1 receptor agonists; SGLT2, sodium glucose cotransporter 2; NS, not significant.